Print

Purpose

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].

Condition

Eligibility

Eligible Ages
Over 16 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority. If these approvals have not been granted, only subjects ≥ 18 years old will be enrolled. To be eligible, adolescent subjects must weight ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit. - Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met. - Documented diagnosis of UC confirmed by endoscopy and histology. Should endoscopy/histology results not be available at screening, results from endoscopies or biopsies taken at screening may be used. - Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader). - Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted). - Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with the contraception requirements described in the protocol. - Subjects able and willing to comply with study visits and procedures as per protocol. - Subjects should be affiliated to a health insurance policy whenever required by a participating country or state.

Exclusion Criteria

  • Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading. - Subjects with primary sclerosing cholangitis or autoimmune hepatitis. - Subjects who have failed on 5-ASA or sulfasalazine therapy only. - Subjects with CD or presence or history of fistula, indeterminate colitis, infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis). - History or current evidence of toxic megacolon, fulminant colitis, bowel perforation. - History of colonic cancer or colonic low grade or high grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of colonic cancer or evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not). - Recent or planned bowel surgery or history of proctocolectomy or partial colectomy or current stoma. - Subjects on antidiarrheals including those working on motility (e.g., loperamide, diphenoxylate with atropine, etc.). - Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.], Saccharomyces boulardii). - Subjects who do not meet the washout period requirements prior to the screening endoscopy - Subjects with the following hematological and biochemical laboratory parameters obtained during the screening period: - Hemoglobin ≤ 8.0 g dL-1 - Absolute neutrophil count < 750 mm-3 - Platelets < 100,000 mm-3 - Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula) - Total serum bilirubin > 1.5 x ULN - Alkaline phosphatase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 x ULN - Subjects with the following conditions (infection): - Subjects with chronic or recurrent grade 3 or grade 4 infection within the last 2 months prior to screening or a history of opportunistic infection while not on immunosuppressive therapy. - Herpes zoster reactivation within the last 2 months prior to screening. - Subjects with active infection at screening or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 1 month of screening or during screening. Fungal infection of nail beds is allowed. - Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridium difficile toxin at screening. If C. difficile is positive, subject may be treated and retested ≥ 2 weeks after completing treatment. - Subjects with HIV infection. - Subjects having acute or chronic hepatitis B infection at screening (positive for hepatitis B surface antigen [HbsAg], or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable HBV DNA, or detectable HBV DNA). - Subjects having acute or chronic hepatitis C infection at screening as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA [assessed centrally] are eligible). - Active tuberculosis (TB) or untreated latent TB are ruled out. For subjects with positive or intermediate QuantiFERON test see study protocol. - Subjects with an uncontrolled ischemic heart disease and/or a history of congestive heart failure with New York Heart Association (NYHA) class 3 or 4 symptoms. - Subjects with a family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female). - Subjects with a history of torsade de pointe (TdP). - Acute or chronic of clinically relevant pulmonary, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history (note: treated autoimmune hypothyroidy and autoimmune diabetes are allowed). - Serious illness requiring hospitalization within 4 weeks prior to screening (except UC flare). - Subjects previously treated with ABX464. - Subjects with a known hypersensitivity to the active substance or to any of the excipients. - WOCBP subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study, or male subject with WOCBP partner who intends to be pregnant during the study. - Illicit drug or alcohol abuse or dependence. - Subjects who received live vaccine within 3 months prior to screening and/or who's planning to receive such a vaccine during the study duration. - Use of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer, and during the study. - Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. - Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ABX464 50mg 		Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  • Drug: ABX464
    Administered once daily in the morning with food
    Other names:
    • Obefazimod
Experimental
ABX464 25mg 		Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  • Drug: ABX464
    Administered once daily in the morning with food
    Other names:
    • Obefazimod
Placebo Comparator
Placebo 		Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  • Drug: Placebo
    Administered once daily in the morning with food

Recruiting Locations

Digestive Health Specialists of the Southeast
Dothan, Alabama 36305
Contact:
Travis Rutland, MD

Lakeview Clinical Research
Guntersville, Alabama 35976
Contact:
William Nixon, MD

GI Alliance
Sun City, Arizona 85351
Contact:
Chirag Trivedi, MD

Del Sol Research Management, LLC
Tucson, Arizona 85715
Contact:
Bassel Kisso, MD

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205-7199
Contact:
Stephan Dehmel, MD

Gastro Care Institute
Lancaster, California 93534
Contact:
Kumaravel Perumalsamy, MD

California Medical Research Associates Inc.
Northridge, California 91324
Contact:
Calin Arimie, MD

Clinnova Research Solutions
Orange, California 92868
Contact:
Amit Bhanvadia, MD

Peak Gastroenterology Associates
Colorado Springs, Colorado 80907
Contact:
Bhaktasharan Patel, MD

Clinical Research Of Brandon, LLC
Brandon, Florida 33511
Contact:
German Alvarez, MD

Access Research Institute
Brooksville, Florida 34613
Contact:
Salman Muddassir, MD

Auzmer Research
Lakeland, Florida 33813
Contact:
Niaz Ausaf, MD

Cfagi, Llc
Maitland, Florida 32751
Contact:
Andria Mushahwar, MD

Medical Professional Clinical Research Center
Miami, Florida 33165
Contact:
Carlos Selema, MD

Gastroenterology Associates of Pensacola, PA
Pensacola, Florida 32503
Contact:
Frederic Newman, MD

Theia Clinical Research Centers, LLC
Temple Terrace, Florida 33617
Contact:
Zubair Farooqui, MD

Eagle Clinical Research
Chicago, Illinois 60621
Contact:
Ayoade Akere, MD

GI Alliance
Glenview, Illinois 60026
Contact:
Nina Merel, MD

GI Alliance
Gurnee, Illinois 60031
Contact:
Jonathan Rosenberg, MD

Indiana University School of Medicine
Indianapolis, Indiana 46202
Contact:
Monika Fischer, MD

University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas 66160
Contact:
Tuba Esfandyari, MD

GI Alliance - Baton Rouge
Baton Rouge, Louisiana 70809
Contact:
Satyaprasad Alapati, MD

Lucida Clinical Trials LLC
New Bedford, Massachusetts 02740
Contact:
Jason Reich, MD

Charlotte Gastroenterology and Hepatology, P.L.L.C
Charlotte, North Carolina 28207
Contact:
John Gardiner Roddey, MD

DSI Research LLC
Springboro, Ohio 45066
Contact:
Anjali Morey, MD

Columbia Digestive Health Research
Columbia, South Carolina 29204
Contact:
Edward Kimbrough, MD

Gastroenterology Associates, PA
Greenville, South Carolina 29607
Contact:
Matthew Barnes, MD

Gastroenterology Center of the MidSouth PC
Germantown, Tennessee 38138
Contact:
Ziad Younes, MD

GI Alliance - Southlake
Austin, Texas 76092
Contact:
Timothy Ritter, MD

Central Texas Clinical Research, LLC
Austin, Texas 78705
Contact:
Cynthia Brinson, MD

Texas Digestive Disease Consultants
Cedar Park, Texas 78613
Contact:
Junaid Siddiqui, MD

Baylor Scott and White
Dallas, Texas 75246
Contact:
Themistocles Dassopoulos, MD

Cook Children's Medical Center
Fort Worth, Texas 76104
Contact:
Clifton Huang, MD

GI Alliance - Garland
Garland, Texas 75044
Contact:
Harry Sarles, MD

Houston Methodist Hospital
Houston, Texas 77030
Contact:
Bincy Abraham, MD

Biopharma Informatic, Inc. Research Center
Houston, Texas 77043
Contact:
Pedro Arguello, MD

Biopharma Informatic, LLC
Houston, Texas 77084
Contact:
James Maher Jr, MD

Gastro Health & Nutrition
Katy, Texas 78754
Contact:
Dharmendra Verma, MD

GI Alliance - San Marcos
San Marcos, Texas 78130
Contact:
Shannon Marek, MD

Texas Gastroenterology Associates
Spring, Texas 77386
Contact:
Maninder Guram, MD

GI Alliance - Webster
Webster, Texas 77598
Contact:
Syed Jafri, MD

Care Access Research LLC
Ogden, Utah 84403
Contact:
Chad Gonzales, MD

University of Utah
Salt Lake City, Utah 84112
Contact:
John Valentine, MD

Gastroenterology Associates of Tidewater
Chesapeake, Virginia 23320
Contact:
Felix Tiongco, MD

Blue Ridge Medical Research
Lynchburg, Virginia 24502
Contact:
Larry Clark, MD

TPMG Clinical Research Williamsburg
Williamsburg, Virginia 23188
Contact:
Frances Jones, MD

More Details

NCT ID
NCT05507203
Status
Recruiting
Sponsor
Abivax S.A.

Study Contact

Laurence Desroys Du Roure, PharmD
+33630031132
laurence.desroysduroure@abivax.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.